Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Aug
18
Today In Oncology
Sugar- vs Artificially Sweetened Beverages and Gastric Cancer Risk
Rezatapopt Shows Activity in TP53 Y220C–Mutated Advanced Ovarian Cancer
High-Risk ERBB2-Negative Breast Cancer Adding Dual Checkpoint Blockade to Neoadjuvant Chemotherapy
TACE Plus Thermal Ablation Improves Survival in Unresectable HCC
Darovasertib Plus Crizotinib May Set New First-Line Standard in HLA-A2–Negative Metastatic Uveal Melanoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo